GSK plc
GSK
$40.07
$0.461.16%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 40.96B | 40.23B | 40.10B | 39.71B | 39.60B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 40.96B | 40.23B | 40.10B | 39.71B | 39.60B |
| Cost of Revenue | 11.59B | 11.30B | 11.30B | 10.96B | 10.77B |
| Gross Profit | 29.37B | 28.94B | 28.80B | 28.75B | 28.83B |
| SG&A Expenses | 13.66B | 13.67B | 13.58B | 13.46B | 11.36B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -650.19M | -503.23M | -468.00M | -1.12B | -1.53B |
| Total Operating Expenses | 32.64B | 32.25B | 32.18B | 30.95B | 28.21B |
| Operating Income | 8.31B | 7.99B | 7.92B | 8.76B | 11.39B |
| Income Before Tax | 5.98B | 5.35B | 4.41B | 4.16B | 6.34B |
| Income Tax Expenses | 823.22M | 742.23M | 666.49M | 563.49M | 890.19M |
| Earnings from Continuing Operations | 5.16K | 4.60K | 3.74K | 3.59K | 5.45K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -729.05M | -623.14M | -481.12M | -429.32M | -357.89M |
| Net Income | 4.43B | 3.98B | 3.26B | 3.17B | 5.09B |
| EBIT | 8.31B | 7.99B | 7.92B | 8.76B | 11.39B |
| EBITDA | 12.82B | 11.75B | 11.34B | 11.78B | 13.91B |
| EPS Basic | 1.09 | 0.97 | 0.80 | 0.78 | 1.25 |
| Normalized Basic EPS | 1.00 | 0.97 | 0.99 | 1.12 | 1.54 |
| EPS Diluted | 1.07 | 0.96 | 0.79 | 0.77 | 1.24 |
| Normalized Diluted EPS | 0.98 | 0.96 | 0.98 | 1.11 | 1.52 |
| Average Basic Shares Outstanding | 16.31B | 16.33B | 16.31B | 16.28B | 16.26B |
| Average Diluted Shares Outstanding | 16.53B | 16.55B | 16.52B | 16.49B | 16.46B |
| Dividend Per Share | 0.82 | 0.79 | 0.78 | 0.77 | 0.76 |
| Payout Ratio | 72.89% | 79.74% | 95.77% | 96.19% | 58.22% |